Zybrivo
Opinion
sintilimab
MedicineHumanOpinion
Italian is available via eTranslation, the European Commission's machine translation service.
Translate to Italian | Important information about machine translation
On 12 November 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zybrivo, intended for the treatment of non-squamous non-small cell lung cancer (NSCLC) in adults.
The applicant for this medicinal product is Fortvita Biologics (Ireland) Limited.
Zybrivo will be available as 100 mg concentrate for solution for infusion. The active substance of Zybrivo is sintilimab, an antineoplastic monoclonal antibody (ATC code: not yet assigned). By blocking the binding of PD-1 to PD-L1 and PD-L2, sintilimab potentiates T-cell responses, including anti-tumour responses.
The benefit of Zybrivo in the first-line setting is an improvement in progression-free survival in patients taking sintilimab in combination with chemotherapy compared with patients taking chemotherapy, as observed in a randomised, multicentre, double‑blind, placebo‑controlled study in adults with locally advanced (stage IIIB, IIIC who were ineligible for radical surgery or chemoradiation with curative intent), metastatic or recurrent (stage IV) non-squamous NSCLC, regardless of PD‑L1 tumour expression status, in whom there were no EGFR or ALK genomic tumour aberrations.
The most common side effects with Zybrivo are anaemia, neutropenia, leukopenia, thrombocytopenia, decreased appetite, nausea, fatigue, aspartate aminotransferase increased, alanine aminotransferase increased, pyrexia, hypothyroidism and rash.
The full indication is:
Zybrivo in combination with pemetrexed and platinum-based chemotherapy is indicated for the first line treatment of adult non squamous non-small cell lung cancer (NSCLC) patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, and who have:
Zybrivo should be initiated and supervised by physicians experienced in the treatment of cancer.
Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.